MAC Clinical Research has reached a key milestone in a Phase 1b study sponsored by Newleos Therapeutics investigating NTX-1955, a potential new treatment for Generalised Anxiety Disorder (GAD), with the first participant now dosed.
The primary objective of this study is to evaluate the safety and tolerability of NTX-1955 following multiple oral doses of NTX-1955 administered to patients with GAD.
GAD is characterised by persistent and excessive worry that can interfere with daily life, often accompanied by symptoms such as restlessness, sleep disturbance and difficulty concentrating.
Dr Shoona Vincent, Vice President of Clinical Science at MAC Clinical Research, explains:
“Dosing the first participant is an important step for this study and for the development of potential new treatments for Generalised Anxiety Disorder. GAD can have a profound impact on people’s daily lives, so studies like this are an essential part of improving how the condition is treated.”
Learn more about our experience delivering GAD studies in this case study.
You can also read more about this study in the press release issued by Newleos.
